protein-design
No description yet: the sentence for this tag has not been written. 10 records carry it: 5 companies, 3 technologies, 1 person, 1 institution.
10 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Chai Discovery San Francisco, CA, US Makes Chai-1 and Chai-2, open-weight structure models used for antibody and binder design. | none | none | ai | ||
Chai-1 / Chai-2 Structure and antibody-design models from Chai Discovery, with Chai-2 reporting high zero-shot antibody hit rates. | none | foundation-model | |||
Cradle Amsterdam / Zurich, NL Cradle is a protein-engineering AI platform used by pharma to optimise antibodies and enzymes. | none | none | ai | ||
David Baker Founder and Director of the Institute for Protein Design · Institute for Protein Design (University of Washington) Nobel laureate biochemist who founded and directs the Institute for Protein Design, which builds new proteins for medicine including cancer therapeutics. | none | none | leadership, clinician-scientist, drug-discovery | ||
ESM3 (EvolutionaryScale) ESM3 is a generative protein model that designed a working fluorescent protein far from any natural sequence. | none | foundation-model | |||
EvolutionaryScale New York, NY, US Spun out of Meta's protein team; makes the ESM3 protein language model that generated a new fluorescent protein. | none | none | ai | ||
Institute for Protein Design (University of Washington) University of Washington · Seattle, US David Baker's institute, where de novo protein design and the RFdiffusion models come from (Nobel Prize in Chemistry 2024). | none | none | ai | ||
Latent Labs London, GB Founded by an AlphaFold co-developer to make protein design programmable; released Latent-X in 2025. | none | none | ai | ||
Profluent Berkeley, CA, US Profluent uses protein language models to design new gene editors (OpenCRISPR-1) and antibodies. | none | none | ai | ||
RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab) The tools that design entirely new proteins to bind a chosen target, now used for cancer binders and antibodies. | none | foundation-model |
